Firms

Sound Bioventures

Sound Bioventures

soundbioventures.com

Scandinavian venture capital firm investing in European and US private biotechnology companies developing novel medicines, especially programmes approaching or undergoing clinical testing. It finances development toward meaningful clinical results, takes board roles and reserves capital for follow-on rounds. Its partners combine biotechnology company-building, pharmaceutical development and venture investing experience. Its neuroscience portfolio includes Teitur Trophics’ neuroprotective peptides, alongside medicines for neuromuscular, immune, cardiovascular and other diseases. The Swedish manager is Sound Bioventures Management AB.

Founded
—
Type
Venture capital

Funds1

  • Sound Bioventures Fund I€116M

    First biotechnology venture fund. The manager reported a final close in 2023 with EUR 116 million in total capital commitments in its January 2024 annual review. Its initial EUR 110 million first close was announced on 4 January 2022. The exact 2023 final-close date is not disclosed in the reviewed evidence, so its inclusion within the October 2023–October 2026 window remains unverified. Investments focus on near-clinical and clinical-stage novel therapeutics in Europe and the US.

Team

Operations and support

Alexander KiellandCOO
Anne Marie SimonOffice Manager
Casper BreumManaging Partner
Ester SklarskyPrincipal
Johan KördelManaging Partner
Laura MunckAnalyst
Linda Spahiu ElvesjöPrincipal

Co-investing

AdBio Partners
CDTI-Innvierte
Columbus Venture Partners
EIC Fund
Hadean Ventures

Investments